NLGN4X and neoplasm: Importantly, in an HLA-A*02:01+ patient population, epitopes of the expressed TAAs will also be presented on the tumours of most patients to the immune system, as CVGBM encodes HLA-A*02:01-restricted epitopes for three of the TAAs (BCAN, NLGN4X, PTPRZ1) and a pan-DR-restricted epitope for the fourth TAA (Survivin), which is presented by many HLA class II molecules [29].